{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:50:15Z","timestamp":1790430615877,"version":"4.1.0"},"reference-count":199,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004335","name":"Harmony Biosciences, LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004335","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sleep Medicine"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.sleep.2019.09.001","type":"journal-article","created":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T11:46:16Z","timestamp":1568202376000},"page":"97-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"special_numbering":"C","title":["Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications"],"prefix":"10.1016","volume":"68","author":[{"given":"Michael J.","family":"Thorpy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard K.","family":"Bogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.sleep.2019.09.001_bib1","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1056\/NEJMra1500587","article-title":"Narcolepsy","volume":"373","author":"Scammell","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.sleep.2019.09.001_bib2","first-page":"845","article-title":"Sleep neurobiology from a clinical perspective","volume":"34","author":"Espa\u00f1a","year":"2011","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2019.09.001_bib3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pneurobio.2015.12.002","article-title":"Challenges in the development of therapeutics for narcolepsy","volume":"152","author":"Black","year":"2017","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.sleep.2019.09.001_bib4","series-title":"The international classification of sleep disorders","author":"American Academy of Sleep Medicine","year":"2014"},{"key":"10.1016\/j.sleep.2019.09.001_bib5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.sleep.2007.03.008","article-title":"Clinical and neurobiological aspects of narcolepsy","volume":"8","author":"Nishino","year":"2007","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2019.09.001_bib6","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.sleep.2008.05.009","article-title":"Prevalence of narcolepsy in king county, Washington, USA","volume":"10","author":"Longstreth","year":"2009","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2019.09.001_bib7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/sleep\/25.2.197","article-title":"The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study","volume":"25","author":"Silber","year":"2002","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2019.09.001_bib8","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/ana.410350612","article-title":"The prevalence of narcolepsy: an epidemiological study of the Finnish Twin Cohort","volume":"35","author":"Hublin","year":"1994","journal-title":"Ann Neurol"},{"key":"10.1016\/j.sleep.2019.09.001_bib9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1192\/bjp.169.4.459","article-title":"Hypnagogic and hypnopompic hallucinations: pathological phenomena?","volume":"169","author":"Ohayon","year":"1996","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.sleep.2019.09.001_bib10","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1212\/WNL.58.12.1826","article-title":"Prevalence of narcolepsy symptomatology and diagnosis in the European general population","volume":"58","author":"Ohayon","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.sleep.2019.09.001_bib11","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1600-0404.2009.01166.x","article-title":"Prevalence of narcolepsy with cataplexy in Norway","volume":"120","author":"Heier","year":"2009","journal-title":"Acta Neurol Scand"},{"issue":"2 Suppl 1","key":"10.1016\/j.sleep.2019.09.001_bib12","first-page":"S16","article-title":"Genetic and familial aspects of narcolepsy","volume":"50","author":"Mignot","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.sleep.2019.09.001_bib13","article-title":"An epidemiological study of nacrolepsy in Japanese","volume":"vol. 1994","author":"Tashiro","year":"1994"},{"key":"10.1016\/j.sleep.2019.09.001_bib14","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/sleep\/10.6.608","article-title":"Narcolepsy is a rare disease in Israel","volume":"10","author":"Lavie","year":"1987","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2019.09.001_bib15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jsmc.2016.10.001","article-title":"Reducing the clinical and socioeconomic burden of narcolepsy by earlier diagnosis and effective treatment","volume":"12","author":"Thorpy","year":"2017","journal-title":"Sleep Med Clin"},{"key":"10.1016\/j.sleep.2019.09.001_bib16","doi-asserted-by":"crossref","first-page":"419","DOI":"10.5664\/jcsm.6494","article-title":"Listening to the patient voice in narcolepsy: diagnostic delay, disease burden, and treatment efficacy","volume":"13","author":"Maski","year":"2017","journal-title":"J\u00a0Clin Sleep Med"},{"key":"10.1016\/j.sleep.2019.09.001_bib17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.5664\/jcsm.5594","article-title":"The humanistic and economic burden of narcolepsy","volume":"12","author":"Flores","year":"2016","journal-title":"J\u00a0Clin Sleep Med"},{"key":"10.1016\/j.sleep.2019.09.001_bib18","first-page":"233","article-title":"The medical and economic burden of narcolepsy: implications for managed care","volume":"10","author":"Thorpy","year":"2017","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.sleep.2019.09.001_bib19","series-title":"The voice of the patient: narcolepsy","author":"US Food and Drug Administration","year":"2014"},{"key":"10.1016\/j.sleep.2019.09.001_bib20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11940-017-0459-0","article-title":"Cataplexy and its mimics: clinical recognition and management","volume":"19","author":"Pillen","year":"2017","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.sleep.2019.09.001_bib21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.sleep.2010.05.010","article-title":"The clinical features of cataplexy: a questionnaire study in narcolepsy patients with and without hypocretin-1 deficiency","volume":"12","author":"Overeem","year":"2011","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2019.09.001_bib22","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.sleep.2014.02.001","article-title":"The Burden of Narcolepsy Disease (BOND) study: health-care utilization and cost findings","volume":"15","author":"Black","year":"2014","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2019.09.001_bib23","doi-asserted-by":"crossref","first-page":"16100","DOI":"10.1038\/nrdp.2016.100","article-title":"Narcolepsy","volume":"3","author":"Kornum","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.sleep.2019.09.001_bib24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.sleep.2014.10.002","article-title":"Clinical and practical considerations in the pharmacologic management of narcolepsy","volume":"16","author":"Thorpy","year":"2015","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2019.09.001_bib25","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.neuron.2017.01.014","article-title":"Neural circuitry of wakefulness and sleep","volume":"93","author":"Scammell","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.sleep.2019.09.001_bib26","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1152\/physrev.00032.2011","article-title":"Control of sleep and wakefulness","volume":"92","author":"Brown","year":"2012","journal-title":"Physiol Rev"},{"key":"10.1016\/j.sleep.2019.09.001_bib27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.smrv.2007.08.010","article-title":"Nocturnal aspects of narcolepsy with cataplexy","volume":"12","author":"Plazzi","year":"2008","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.sleep.2019.09.001_bib28","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1093\/sleep\/17.7.590","article-title":"Patterns of sleep and wakefulness in treated narcoleptic subjects","volume":"17","author":"Rogers","year":"1994","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2019.09.001_bib29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/sleep\/9.1.205","article-title":"Excessive daytime sleepiness and the pathophysiology of narcolepsy-cataplexy: a laboratory perspective","volume":"9","author":"Broughton","year":"1986","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2019.09.001_bib30","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jamaneurol.2013.1589","article-title":"Nocturnal rapid eye movement sleep latency for identifying patients with narcolepsy\/hypocretin deficiency","volume":"70","author":"Andlauer","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.sleep.2019.09.001_bib31","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/nature04284","article-title":"Hypothalamic regulation of sleep and circadian rhythms","volume":"437","author":"Saper","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.sleep.2019.09.001_bib32","doi-asserted-by":"crossref","first-page":"9996","DOI":"10.1523\/JNEUROSCI.18-23-09996.1998","article-title":"Neurons containing hypocretin (orexin) project to multiple neuronal systems","volume":"18","author":"Peyron","year":"1998","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.sleep.2019.09.001_bib33","first-page":"19","article-title":"Effect of the wake-promoting agent modafinil on sleep-promoting neurons from the ventrolateral preoptic nucleus: an in\u00a0vitro pharmacologic study","volume":"27","author":"Gallopin","year":"2004","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2019.09.001_bib34","doi-asserted-by":"crossref","first-page":"R1237","DOI":"10.1016\/j.cub.2017.10.026","article-title":"The biology of REM sleep","volume":"27","author":"Peever","year":"2017","journal-title":"Curr Biol"},{"key":"10.1016\/j.sleep.2019.09.001_bib35","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsy068","article-title":"Melanin-concentrating hormone-expressing neurons adjust slow-wave sleep dynamics to catalyze paradoxical (REM) sleep","volume":"41","author":"Varin","year":"2018","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2019.09.001_bib36","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.neuroscience.2016.08.046","article-title":"Melanin-concentrating hormone neurons specifically promote rapid eye movement sleep in mice","volume":"336","author":"Vetrivelan","year":"2016","journal-title":"Neuroscience"},{"key":"10.1016\/j.sleep.2019.09.001_bib37","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.neuroscience.2019.03.020","article-title":"Ventrolateral periaqueductal gray mediates rapid eye movement sleep regulation by melanin-concentrating hormone neurons","volume":"406","author":"Kroeger","year":"2019","journal-title":"Neuroscience"},{"key":"10.1016\/j.sleep.2019.09.001_bib38","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.smrv.2010.06.004","article-title":"Histamine in the regulation of wakefulness","volume":"15","author":"Thakkar","year":"2011","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.sleep.2019.09.001_bib39","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsy183","article-title":"Histamine: neural circuits and new medications","volume":"42","author":"Scammell","year":"2019","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2019.09.001_bib40","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrneurol.2015.99","article-title":"Interactions of the histamine and hypocretin systems in CNS disorders","volume":"11","author":"Shan","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.sleep.2019.09.001_bib41","doi-asserted-by":"crossref","first-page":"14423","DOI":"10.1523\/JNEUROSCI.2604-09.2009","article-title":"Orexin\/hypocretin and histamine: distinct roles in the control of wakefulness demonstrated using knock-out mouse models","volume":"29","author":"Anaclet","year":"2009","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.sleep.2019.09.001_bib42","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1073\/pnas.1012456108","article-title":"Orexin receptor 2 expression in the posterior hypothalamus rescues sleepiness in narcoleptic mice","volume":"108","author":"Mochizuki","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.sleep.2019.09.001_bib43","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/ana.10444","article-title":"The neurobiology, diagnosis, and treatment of narcolepsy","volume":"53","author":"Scammell","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.sleep.2019.09.001_bib44","doi-asserted-by":"crossref","first-page":"12305","DOI":"10.1523\/JNEUROSCI.2630-12.2012","article-title":"Narcolepsy: neural mechanisms of sleepiness and cataplexy","volume":"32","author":"Burgess","year":"2012","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.sleep.2019.09.001_bib45","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nrneurol.2014.97","article-title":"Cataplexy--clinical aspects, pathophysiology and management strategy","volume":"10","author":"Dauvilliers","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.sleep.2019.09.001_bib46","first-page":"159","article-title":"Treatment paradigms for cataplexy in narcolepsy: past, present, and future","volume":"7","author":"Swick","year":"2015","journal-title":"Nat Sci Sleep"},{"key":"10.1016\/j.sleep.2019.09.001_bib47","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1093\/sleep\/30.12.1705","article-title":"Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin","volume":"30","author":"Morgenthaler","year":"2007","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2019.09.001_bib48","series-title":"Sunosi\u2122 (solriamfetol) tablets, for oral use, CIV","year":"2019"},{"key":"10.1016\/j.sleep.2019.09.001_bib49","series-title":"WAKIX\u00ae (pitolisant) tablets, for oral use","year":"2019"},{"key":"10.1016\/j.sleep.2019.09.001_bib50","series-title":"Xyrem\u00ae (sodium oxybate) oral solution CIII","year":"2018"},{"key":"10.1016\/j.sleep.2019.09.001_bib51","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.sleep.2017.01.002","article-title":"The european Medicines agency review of pitolisant for treatment of narcolepsy: summary of the scientific assessment by the committee for medicinal products for human use","volume":"33","author":"Kollb-Sielecka","year":"2017","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2019.09.001_bib52","series-title":"Wakix summary of product characteristics [SPC]","year":"2016"},{"key":"10.1016\/j.sleep.2019.09.001_bib53","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1476-5381.2011.01286.x","article-title":"The histamine H3 receptor: from discovery to clinical trials with pitolisant","volume":"163","author":"Schwartz","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.sleep.2019.09.001_bib54","series-title":"Dexedrine\u00ae (dextroamphetamine sulfate) spansule\u00ae sustained-release capsules CII","year":"2017"},{"key":"10.1016\/j.sleep.2019.09.001_bib55","series-title":"Zenzedi\u00ae (dextroamphetamine sulfate tablets, USP) CII","year":"2017"},{"key":"10.1016\/j.sleep.2019.09.001_bib56","series-title":"Adderall\u00ae (dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate tablets) CII.","year":"2017"},{"key":"10.1016\/j.sleep.2019.09.001_bib57","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00787-012-0286-5","article-title":"Amfetamine and methylphenidate medications for attention-deficit\/hyperactivity disorder: complementary treatment options","volume":"21","author":"Hodgkins","year":"2012","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.sleep.2019.09.001_bib58","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ejphar.2015.07.044","article-title":"Psychostimulants affect dopamine transmission through both dopamine transporter-dependent and independent mechanisms","volume":"764","author":"dela Pe\u00f1a","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.sleep.2019.09.001_bib59","series-title":"Ritalin\u00ae methylphenidate hydrochloride USP tablets CII","year":"2013"},{"key":"10.1016\/j.sleep.2019.09.001_bib60","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0025-6196(11)64618-1","article-title":"Methylphenidate: its pharmacology and uses","volume":"75","author":"Challman","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.sleep.2019.09.001_bib61","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/hup.579","article-title":"Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects","volume":"19","author":"Leonard","year":"2004","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.sleep.2019.09.001_bib62","series-title":"Provigil\u00ae (modafinil) tablets, for oral use, C-IV","year":"2015"},{"key":"10.1016\/j.sleep.2019.09.001_bib63","series-title":"Modafinil summary of product characteristics, labelling and package leaflet","year":"2010"},{"key":"10.1016\/j.sleep.2019.09.001_bib64","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3389\/fneur.2013.00139","article-title":"Modafinil as a catecholaminergic agent: empirical evidence and unanswered questions","volume":"4","author":"Wisor","year":"2013","journal-title":"Front Neurol"},{"key":"10.1016\/j.sleep.2019.09.001_bib65","series-title":"Nuvigil\u00ae (armodafinil) tablets, for oral use, C-IV","year":"2017"},{"key":"10.1016\/j.sleep.2019.09.001_bib66","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.biopsych.2012.03.022","article-title":"R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse","volume":"72","author":"Loland","year":"2012","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.sleep.2019.09.001_bib67","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1124\/jpet.118.248120","article-title":"Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor","volume":"366","author":"Baladi","year":"2018","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.sleep.2019.09.001_bib68","article-title":"A\u00a0phase I, randomized, crossover, open-label study of the pharmacokinetics of solriamfetol (JZP-110) in healthy adult subjects with and without food","volume":"6","author":"Zomorodi","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.sleep.2019.09.001_bib69","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/j.sleep.2017.11.961","article-title":"A\u00a0randomized, placebo-controlled, phase 3 study of the safety and efficacy of solriamefetol (JZP - 110) for the treatment of excessive sleepiness in patients with narcolepsy","volume":"40","author":"Thorpy","year":"2017","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2019.09.001_bib70","series-title":"Effexor XR\u00ae (venlafaxine extended-release) capsules","year":"2017"},{"key":"10.1016\/j.sleep.2019.09.001_bib71","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s13311-012-0150-9","article-title":"A\u00a0practical guide to the therapy of narcolepsy and hypersomnia syndromes","volume":"9","author":"Mignot","year":"2012","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.sleep.2019.09.001_bib72","series-title":"Strattera\u00ae (atomoxetine hydrochloride) capsules for oral use","year":"2017"},{"key":"10.1016\/j.sleep.2019.09.001_bib73","series-title":"Edronax summary of product characteristics [SPC]","year":"2015"},{"key":"10.1016\/j.sleep.2019.09.001_bib74","series-title":"Prozac\u00ae (fluoxetine hydrochloride) for oral use","year":"2017"},{"key":"10.1016\/j.sleep.2019.09.001_bib75","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1523\/JNEUROSCI.21-05-01787.2001","article-title":"Dopaminergic role in stimulant-induced wakefulness","volume":"21","author":"Wisor","year":"2001","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.sleep.2019.09.001_bib76","doi-asserted-by":"crossref","first-page":"481","DOI":"10.55782\/ane-2007-1664","article-title":"Dopamine, learning, and reward-seeking behavior","author":"Arias-Carri\u00f3n","year":"2007","journal-title":"Acta Neurobiol Exp (Wars)"},{"key":"10.1016\/j.sleep.2019.09.001_bib77","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.cell.2015.07.046","article-title":"The brain on drugs: from reward to addiction","volume":"162","author":"Volkow","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.sleep.2019.09.001_bib78","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1212\/WNL.9.3.171","article-title":"Treatment of narcolepsy with Ritalin","volume":"9","author":"Yoss","year":"1959","journal-title":"Neurology"},{"key":"10.1016\/j.sleep.2019.09.001_bib79","doi-asserted-by":"crossref","first-page":"974","DOI":"10.2105\/AJPH.2007.110593","article-title":"America's first amphetamine epidemic 1929-1971: a quantitative and qualitative retrospective with implications for the present","volume":"98","author":"Rasmussen","year":"2008","journal-title":"Am J Public Health"},{"key":"10.1016\/j.sleep.2019.09.001_bib80","first-page":"159","article-title":"Methylphenidate abuse and psychiatric side effects","volume":"2","author":"Morton","year":"2000","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"10.1016\/j.sleep.2019.09.001_bib81","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1017\/S1092852914000583","article-title":"Mechanism of action of narcolepsy medications","volume":"19","author":"Gowda","year":"2014","journal-title":"CNS Spectr"},{"key":"10.1016\/j.sleep.2019.09.001_bib82","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/ana.410430115","article-title":"Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy","volume":"43","year":"1998","journal-title":"Ann Neurol"},{"key":"10.1016\/j.sleep.2019.09.001_bib83","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1212\/WNL.54.5.1166","article-title":"Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy","volume":"54","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.sleep.2019.09.001_bib84","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1185\/030079906X100050","article-title":"The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy","volume":"22","author":"Harsh","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.sleep.2019.09.001_bib85","first-page":"RA177","article-title":"Modafinil for narcolepsy: systematic review and meta-analysis","volume":"16","author":"Golicki","year":"2010","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.sleep.2019.09.001_bib86","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.neuroscience.2005.02.003","article-title":"Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil","volume":"132","author":"Wisor","year":"2005","journal-title":"Neuroscience"},{"key":"10.1016\/j.sleep.2019.09.001_bib87","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2147\/NDT.S3004","article-title":"Armodafinil in the treatment of sleep\/wake disorders","volume":"6","author":"Schwartz","year":"2010","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.sleep.2019.09.001_bib88","first-page":"49","article-title":"Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants","volume":"1","author":"Nishino","year":"1998","journal-title":"Sleep Res Online"},{"key":"10.1016\/j.sleep.2019.09.001_bib89","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1001\/jama.2009.351","article-title":"Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications","volume":"301","author":"Volkow","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.sleep.2019.09.001_bib90","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/sleep\/17.5.436","article-title":"Modafinil binds to the dopamine uptake carrier site with low affinity","volume":"17","author":"Mignot","year":"1994","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2019.09.001_bib91","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1124\/jpet.106.106583","article-title":"Modafinil occupies dopamine and norepinephrine transporters in\u00a0vivo and modulates the transporters and trace amine activity in\u00a0vitro","volume":"319","author":"Madras","year":"2006","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.sleep.2019.09.001_bib92","doi-asserted-by":"crossref","first-page":"8462","DOI":"10.1523\/JNEUROSCI.1819-08.2008","article-title":"Dopaminergic D1 and D2 receptors are essential for the arousal effect of modafinil","volume":"28","author":"Qu","year":"2008","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.sleep.2019.09.001_bib93","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/syn.20647","article-title":"Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil","volume":"63","author":"Seeman","year":"2009","journal-title":"Synapse"},{"key":"10.1016\/j.sleep.2019.09.001_bib94","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.biopsych.2009.12.015","article-title":"Action of modafinil--increased motivation via the dopamine transporter inhibition and D1 receptors?","volume":"67","author":"Young","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.sleep.2019.09.001_bib95","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1124\/jpet.108.146142","article-title":"Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil","volume":"329","author":"Zolkowska","year":"2009","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.sleep.2019.09.001_bib96","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.sleep.2015.05.013","article-title":"Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy","volume":"16","author":"Bogan","year":"2015","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2019.09.001_bib97","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.5665\/sleep.5968","article-title":"Effect of oral JZP-110 (ADX-N05) on wakefulness and sleepiness in adults with narcolepsy: a phase 2b study","volume":"39","author":"Ruoff","year":"2016","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2019.09.001_bib98","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ana.25423","article-title":"A\u00a0randomized study of solriamfetol for excessive sleepiness in narcolepsy","volume":"85","author":"Thorpy","year":"2019","journal-title":"Ann Neurol"},{"key":"10.1016\/j.sleep.2019.09.001_bib99","doi-asserted-by":"crossref","first-page":"9734","DOI":"10.1523\/JNEUROSCI.5632-12.2013","article-title":"Amygdala lesions reduce cataplexy in orexin knock-out mice","volume":"33","author":"Burgess","year":"2013","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.sleep.2019.09.001_bib100","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1113\/jphysiol.2003.052134","article-title":"Activity of dorsal raphe cells across the sleep-waking cycle and during cataplexy in narcoleptic dogs","volume":"554","author":"Wu","year":"2004","journal-title":"J\u00a0Physiol"},{"key":"10.1016\/j.sleep.2019.09.001_bib101","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0306-4522(98)00600-9","article-title":"Locus coeruleus neurons: cessation of activity during cataplexy","volume":"91","author":"Wu","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.sleep.2019.09.001_bib102","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0301-0082(96)00070-6","article-title":"Pharmacological aspects of human and canine narcolepsy","volume":"52","author":"Nishino","year":"1997","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.sleep.2019.09.001_bib103","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/syn.10009","article-title":"Serotonin (1A) receptor ligands act on norepinephrine neuron firing through excitatory amino acid and GABA(A) receptors: a microiontophoretic study in the rat locus coeruleus","volume":"42","author":"Szabo","year":"2001","journal-title":"Synapse"},{"key":"10.1016\/j.sleep.2019.09.001_bib104","doi-asserted-by":"crossref","first-page":"E3526","DOI":"10.1073\/pnas.1614552114","article-title":"Serotonin neurons in the dorsal raphe mediate the anticataplectic action of orexin neurons by reducing amygdala activity","volume":"114","author":"Hasegawa","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.sleep.2019.09.001_bib105","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1080\/14656566.2017.1323877","article-title":"Pharmacological management of narcolepsy with and without cataplexy","volume":"18","author":"Kallweit","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.sleep.2019.09.001_bib106","first-page":"CD003724","article-title":"Antidepressant drugs for narcolepsy","author":"Vignatelli","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.sleep.2019.09.001_bib107","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.sleep.2008.04.004","article-title":"Exacerbation of cataplexy following gradual withdrawal of antidepressants: manifestation of probable protracted rebound cataplexy","volume":"10","author":"Ristanovic","year":"2009","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2019.09.001_bib108","doi-asserted-by":"crossref","first-page":"715","DOI":"10.5664\/jcsm.2848","article-title":"Status cataplecticus precipitated by abrupt withdrawal of venlafaxine","volume":"9","author":"Wang","year":"2013","journal-title":"J\u00a0Clin Sleep Med"},{"key":"10.1016\/j.sleep.2019.09.001_bib109","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/sleep\/16.8.706","article-title":"Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds","volume":"16","author":"Nishino","year":"1993","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2019.09.001_bib110","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11940-015-0347-4","article-title":"Update on therapy for narcolepsy","volume":"17","author":"Thorpy","year":"2015","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.sleep.2019.09.001_bib111","series-title":"European handbook of neurological management","first-page":"513","article-title":"Management of narcolepsy in adults","author":"Billiard","year":"2011"},{"key":"10.1016\/j.sleep.2019.09.001_bib112","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/00002826-199508000-00002","article-title":"Selegeline hydrochloride treatment in narcolepsy. A double-blind, placebo-controlled study","volume":"18","author":"Mayer","year":"1995","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.sleep.2019.09.001_bib113","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/sleep\/28.9.1189","article-title":"Atomoxetine also effective in patients suffering from narcolepsy?","volume":"28","author":"Niederhofer","year":"2005","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2019.09.001_bib114","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/sleep\/24.3.282","article-title":"Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study","volume":"24","author":"Larrosa","year":"2001","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2019.09.001_bib115","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.smrv.2010.08.002","article-title":"The neuronal network responsible for paradoxical sleep and its dysfunctions causing narcolepsy and rapid eye movement (REM) behavior disorder","volume":"15","author":"Luppi","year":"2011","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.sleep.2019.09.001_bib116","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1523\/JNEUROSCI.4070-15.2017","article-title":"GABA cells in the central nucleus of the amygdala promote cataplexy","volume":"37","author":"Snow","year":"2017","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.sleep.2019.09.001_bib117","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1523\/JNEUROSCI.4065-15.2017","article-title":"GABAergic neurons of the central amygdala promote cataplexy","volume":"37","author":"Mahoney","year":"2017","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.sleep.2019.09.001_bib118","first-page":"42","article-title":"A\u00a0randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy","volume":"25","year":"2002","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2019.09.001_bib119","doi-asserted-by":"crossref","first-page":"391","DOI":"10.5664\/jcsm.26368","article-title":"A\u00a0double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy","volume":"1","year":"2005","journal-title":"J\u00a0Clin Sleep Med"},{"key":"10.1016\/j.sleep.2019.09.001_bib120","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.sleep.2005.03.010","article-title":"Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients","volume":"6","year":"2005","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2019.09.001_bib121","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/sleep\/29.7.939","article-title":"Sodium oxybate improves excessive daytime sleepiness in narcolepsy","volume":"29","author":"Black","year":"2006","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2019.09.001_bib122","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.sleep.2009.05.004","article-title":"The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy","volume":"10","author":"Black","year":"2009","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2019.09.001_bib123","doi-asserted-by":"crossref","first-page":"596","DOI":"10.5664\/jcsm.27994","article-title":"The nightly use of sodium oxybate is associated with a reduction in nocturnal sleep disruption: a double-blind, placebo-controlled study in patients with narcolepsy","volume":"6","author":"Black","year":"2010","journal-title":"J\u00a0Clin Sleep Med"},{"key":"10.1016\/j.sleep.2019.09.001_bib124","first-page":"31","article-title":"A\u00a012-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy","volume":"26","year":"2003","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2019.09.001_bib125","doi-asserted-by":"crossref","first-page":"993","DOI":"10.2165\/00023210-200620120-00004","article-title":"gamma-Hydroxybutyrate\/sodium oxybate: neurobiology, and impact on sleep and wakefulness","volume":"20","author":"Pardi","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1016\/j.sleep.2019.09.001_bib126","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.2174\/138161211796197098","article-title":"A\u00a0review of sodium oxybate and baclofen in the treatment of sleep disorders","volume":"17","author":"Brown","year":"2011","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.sleep.2019.09.001_bib127","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.biopsych.2003.12.013","article-title":"Effects of sustained gamma-hydroxybutyrate treatments on spontaneous and evoked firing activity of locus coeruleus norepinephrine neurons","volume":"55","author":"Szabo","year":"2004","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.sleep.2019.09.001_bib128","doi-asserted-by":"crossref","first-page":"6485","DOI":"10.1523\/JNEUROSCI.0080-14.2014","article-title":"GABAB agonism promotes sleep and reduces cataplexy in murine narcolepsy","volume":"34","author":"Black","year":"2014","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.sleep.2019.09.001_bib129","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2147\/NSS.S86649","article-title":"Baclofen for narcolepsy with cataplexy: two cases","volume":"7","author":"Lee","year":"2015","journal-title":"Nat Sci Sleep"},{"key":"10.1016\/j.sleep.2019.09.001_bib130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pediatrneurol.2018.10.020","article-title":"Management of excessive daytime sleepiness in narcolepsy with baclofen","volume":"93","author":"Morse","year":"2019","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.sleep.2019.09.001_bib131","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pediatrneurol.2009.02.008","article-title":"Narcolepsy: action of two gamma-aminobutyric acid type B agonists, baclofen and sodium oxybate","volume":"41","author":"Huang","year":"2009","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.sleep.2019.09.001_bib132","doi-asserted-by":"crossref","first-page":"955","DOI":"10.5664\/jcsm.3004","article-title":"Disrupted nighttime sleep in narcolepsy","volume":"9","author":"Roth","year":"2013","journal-title":"J\u00a0Clin Sleep Med"},{"key":"10.1016\/j.sleep.2019.09.001_bib133","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.pharmthera.2008.10.003","article-title":"Behavioral analyses of GHB: receptor mechanisms","volume":"121","author":"Carter","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.sleep.2019.09.001_bib134","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1124\/pr.114.010249","article-title":"International union of basic and clinical pharmacology. XCVIII. Histamine receptors","volume":"67","author":"Panula","year":"2015","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.sleep.2019.09.001_bib135","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1152\/physrev.00043.2007","article-title":"Histamine in the nervous system","volume":"88","author":"Haas","year":"2008","journal-title":"Physiol Rev"},{"key":"10.1016\/j.sleep.2019.09.001_bib136","doi-asserted-by":"crossref","first-page":"7695","DOI":"10.1523\/JNEUROSCI.22-17-07695.2002","article-title":"Anatomical, physiological, and pharmacological characteristics of histidine decarboxylase knock-out mice: evidence for the role of brain histamine in behavioral and sleep-wake control","volume":"22","author":"Parmentier","year":"2002","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.sleep.2019.09.001_bib137","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1124\/jpet.110.170134","article-title":"Histamine H3 receptors and sleep-wake regulation","volume":"336","author":"Lin","year":"2011","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.sleep.2019.09.001_bib138","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.neuropharm.2005.03.001","article-title":"Histamine excites noradrenergic neurons in locus coeruleus in rats","volume":"49","author":"Korotkova","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.sleep.2019.09.001_bib139","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1212\/WNL.0b013e3181f884b1","article-title":"Histamine in the CNS: multiple functions and potential neurologic implications","volume":"75","author":"Benarroch","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.sleep.2019.09.001_bib140","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/327117a0","article-title":"Highly potent and selective ligands for histamine H3-receptors","volume":"327","author":"Arrang","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.sleep.2019.09.001_bib141","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1124\/jpet.106.111039","article-title":"BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist\/antagonist at the human histamine H3 receptor: preclinical pharmacology","volume":"320","author":"Ligneau","year":"2007","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.sleep.2019.09.001_bib142","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/bph.12221","article-title":"Histamine H3 receptors, the complex interaction with dopamine and its implications for addiction","volume":"170","author":"Ellenbroek","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.sleep.2019.09.001_bib143","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S1474-4422(13)70225-4","article-title":"Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial","volume":"12","author":"Dauvilliers","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.sleep.2019.09.001_bib144","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1474-4422(16)30333-7","article-title":"Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial","volume":"16","author":"Szakacs","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.sleep.2019.09.001_bib145","series-title":"Long-term evaluation of safety and efficacy of pitolisant in narcolepsy: Harmony 3 study","author":"Dauvilliers","year":"2018"},{"key":"10.1016\/j.sleep.2019.09.001_bib146","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/NSS.S103462","article-title":"Update on the treatment of narcolepsy: clinical efficacy of pitolisant","volume":"9","author":"Calik","year":"2017","journal-title":"Nat Sci Sleep"},{"key":"10.1016\/j.sleep.2019.09.001_bib147","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.nbd.2007.12.003","article-title":"An inverse agonist of the histamine H3 receptor improves wakefulness in narcolepsy: studies in orexin-\/- mice and patients","volume":"30","author":"Lin","year":"2008","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.sleep.2019.09.001_bib148","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1021\/acs.jmedchem.8b01280","article-title":"Discovery and development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride (SUVN-G3031): a novel, potent, selective, and orally active histamine H3 receptor inverse agonist with robust wake-promoting activity","volume":"62","author":"Nirogi","year":"2019","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.sleep.2019.09.001_bib149","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/13543784.2018.1459561","article-title":"An overview of hypocretin based therapy in narcolepsy","volume":"27","author":"Takenoshita","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.sleep.2019.09.001_bib150","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.smrv.2018.09.006","article-title":"Neurobiological and immunogenetic aspects of narcolepsy: implications for pharmacotherapy","volume":"43","author":"Szabo","year":"2019","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.sleep.2019.09.001_bib151","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1002\/jps.21604","article-title":"Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system","volume":"98","author":"Dhuria","year":"2009","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.sleep.2019.09.001_bib152","doi-asserted-by":"crossref","first-page":"14239","DOI":"10.1523\/JNEUROSCI.3878-07.2007","article-title":"Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates","volume":"27","author":"Deadwyler","year":"2007","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.sleep.2019.09.001_bib153","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.sleep.2011.06.015","article-title":"Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy","volume":"12","author":"Baier","year":"2011","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2019.09.001_bib154","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bbr.2013.12.045","article-title":"The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy","volume":"262","author":"Weinhold","year":"2014","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.sleep.2019.09.001_bib155","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1073\/pnas.1700499114","article-title":"Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models","volume":"114","author":"Irukayama-Tomobe","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.sleep.2019.09.001_bib156","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/ana.22587","article-title":"Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China","volume":"70","author":"Han","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.sleep.2019.09.001_bib157","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.conb.2013.04.013","article-title":"The autoimmune basis of narcolepsy","volume":"23","author":"Mahlios","year":"2013","journal-title":"Curr Opin Neurobiol"},{"key":"10.1016\/j.sleep.2019.09.001_bib158","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jsmc.2017.03.004","article-title":"The immune basis of narcolepsy: what is the evidence?","volume":"12","author":"Taheri","year":"2017","journal-title":"Sleep Med Clin"},{"key":"10.1016\/j.sleep.2019.09.001_bib159","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11910-018-0851-5","article-title":"Narcolepsy associated with Pandemrix\u00a0vaccine","volume":"18","author":"Sarkanen","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.sleep.2019.09.001_bib160","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41583-018-0097-x","article-title":"The neurobiological basis of narcolepsy","volume":"20","author":"Mahoney","year":"2019","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.sleep.2019.09.001_bib161","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.sleep.2014.01.015","article-title":"Delayed diagnosis of narcolepsy: characterization and impact","volume":"15","author":"Thorpy","year":"2014","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2019.09.001_bib162","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1055\/s-0030-1267993","article-title":"Intravenous immunoglobulin treatment and screening for hypocretin neuron-specific autoantibodies in recent onset childhood narcolepsy with cataplexy","volume":"41","author":"Knudsen","year":"2010","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.sleep.2019.09.001_bib163","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1212\/WNL.0b013e3181bd1344","article-title":"Normalization of hypocretin-1 in narcolepsy after intravenous immunoglobulin treatment","volume":"73","author":"Dauvilliers","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.sleep.2019.09.001_bib164","first-page":"1549","article-title":"Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy","volume":"255","author":"Plazzi","year":"2008","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.sleep.2019.09.001_bib165","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/ana.20339","article-title":"Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset","volume":"56","author":"Dauvilliers","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.sleep.2019.09.001_bib166","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1046\/j.1365-2869.2003.00380.x","article-title":"Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy","volume":"12","author":"Lecendreux","year":"2003","journal-title":"J\u00a0Sleep Res"},{"key":"10.1016\/j.sleep.2019.09.001_bib167","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.sleep.2016.01.024","article-title":"Steroid therapy ameliorated cataplexy in three children with recent-onset of narcolepsy","volume":"29","author":"Miyata","year":"2017","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2019.09.001_bib168","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1093\/sleep\/26.7.809","article-title":"Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin-deficiency narcolepsy","volume":"26","author":"Hecht","year":"2003","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2019.09.001_bib169","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/ana.20603","article-title":"Late-onset narcolepsy presenting as rapidly progressing muscle weakness: response to plasmapheresis","volume":"58","author":"Chen","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.sleep.2019.09.001_bib170","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/sleep\/9.1.269","article-title":"Treatment of narcolepsy with codeine","volume":"9","author":"Fry","year":"1986","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2019.09.001_bib171","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao4953","article-title":"Opiates increase the number of hypocretin-producing cells in human and mouse brain and reverse cataplexy in a mouse model of narcolepsy","volume":"10","author":"Thannickal","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.sleep.2019.09.001_bib172","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.sleep.2013.03.002","article-title":"Narcolepsy is complicated by high medical and psychiatric comorbidities: a comparison with the general population","volume":"14","author":"Ohayon","year":"2013","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2019.09.001_bib173","doi-asserted-by":"crossref","first-page":"e479","DOI":"10.1212\/WNL.0000000000004911","article-title":"Effect of psychostimulants on blood pressure profile and endothelial function in narcolepsy","volume":"90","author":"Bosco","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.sleep.2019.09.001_bib174","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0896-6273(00)80111-7","article-title":"Addiction to cocaine and amphetamine","volume":"16","author":"Hyman","year":"1996","journal-title":"Neuron"},{"key":"10.1016\/j.sleep.2019.09.001_bib175","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/sleep\/32.11.1407","article-title":"Rebound hypersomnolence, stimulant abuse, and DAT-mediated dopamine release","volume":"32","author":"Nishino","year":"2009","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2019.09.001_bib176","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/mp.2008.90","article-title":"Potential adverse effects of amphetamine treatment on brain and behavior: a review","volume":"14","author":"Berman","year":"2009","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.sleep.2019.09.001_bib177","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1056\/NEJMoa1813751","article-title":"Psychosis with methylphenidate or amphetamine in patients with ADHD","volume":"380","author":"Moran","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.sleep.2019.09.001_bib178","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-2486","article-title":"Stimulant medication and psychotic symptoms in offspring of parents with mental illness","volume":"137","author":"MacKenzie","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.sleep.2019.09.001_bib179","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/10550490601082775","article-title":"Abuse liability of medications used to treat attention-deficit\/hyperactivity disorder (ADHD)","volume":"16","author":"Kollins","year":"2007","journal-title":"Am J Addict"},{"key":"10.1016\/j.sleep.2019.09.001_bib180","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.neuropharm.2008.05.022","article-title":"Imaging dopamine's role in drug abuse and addiction","volume":"56","author":"Volkow","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.sleep.2019.09.001_bib181","series-title":"Principles and practice of sleep medicine","first-page":"511","article-title":"Wake-promoting medications: basic mechanisms and pharmacology","author":"Nishino","year":"2011"},{"key":"10.1016\/j.sleep.2019.09.001_bib182","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/026988110001400107","article-title":"An evaluation of the abuse potential of modafinil using methylphenidate as a reference","volume":"14","author":"Jasinski","year":"2000","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.sleep.2019.09.001_bib183","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1038\/npp.2009.3","article-title":"How to keep the brain awake? The complex molecular pharmacogenetics of wake promotion","volume":"34","author":"Hasan","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.sleep.2019.09.001_bib184","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1177\/0269881118796814","article-title":"A\u00a0randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor","volume":"32","author":"Carter","year":"2018","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.sleep.2019.09.001_bib185","series-title":"Nacrolepsy: diagnosis and management. Principles and practices of sleep medicine","first-page":"957","author":"Guilleminault","year":"2011"},{"key":"10.1016\/j.sleep.2019.09.001_bib186","series-title":"Anafranil\u2122 (clomipramine hydrochloride) capsules USP (25 mg, 50 mg, and 75 mg)","year":"2012"},{"key":"10.1016\/j.sleep.2019.09.001_bib187","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/NSS.S103467","article-title":"New developments in the management of narcolepsy","volume":"9","author":"Abad","year":"2017","journal-title":"Nat Sci Sleep"},{"key":"10.1016\/j.sleep.2019.09.001_bib188","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.sleep.2010.07.022","article-title":"Changing demographics in REM sleep behavior disorder: possible effect of autoimmunity and antidepressants","volume":"12","author":"Ju","year":"2011","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2019.09.001_bib189","doi-asserted-by":"crossref","first-page":"365","DOI":"10.5664\/jcsm.27549","article-title":"Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion","volume":"5","author":"Wang","year":"2009","journal-title":"J\u00a0Clin Sleep Med"},{"key":"10.1016\/j.sleep.2019.09.001_bib190","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s40265-016-0620-1","article-title":"Pitolisant: first global approval","volume":"76","author":"Syed","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.sleep.2019.09.001_bib191","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/bph.12149","article-title":"Preclinical evaluation of the abuse potential of pitolisant, a histamine H3 receptor inverse agonist\/antagonist compared with modafinil","volume":"169","author":"Uguen","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.sleep.2019.09.001_bib192","article-title":"Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist\/inverse agonist for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy","author":"Setnik","year":"2019","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2019.09.001_bib193","first-page":"1","article-title":"Solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy","author":"Yang","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.sleep.2019.09.001_bib194","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1517\/13543784.7.1.99","article-title":"Modafinil: a novel stimulant for the treatment of narcolepsy","volume":"7","author":"Scammell","year":"1998","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.sleep.2019.09.001_bib195","doi-asserted-by":"crossref","first-page":"787","DOI":"10.5665\/sleep.4676","article-title":"Increased lucid dreaming frequency in narcolepsy","volume":"38","author":"Rak","year":"2015","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2019.09.001_bib196","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.sleep.2016.04.014","article-title":"Sodium oxybate for idiopathic REM sleep behavior disorder: a report on two patients","volume":"32","author":"Moghadam","year":"2017","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2019.09.001_bib197","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.sleep.2015.10.005","article-title":"Benefits and risk of sodium oxybate in idiopathic hypersomnia versus narcolepsy type 1: a chart review","volume":"17","author":"Leu-Semenescu","year":"2016","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2019.09.001_bib198","doi-asserted-by":"crossref","first-page":"427","DOI":"10.5664\/jcsm.4598","article-title":"Time to response with sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy","volume":"11","author":"Bogan","year":"2015","journal-title":"J\u00a0Clin Sleep Med"},{"key":"10.1016\/j.sleep.2019.09.001_bib199","doi-asserted-by":"crossref","first-page":"A250","DOI":"10.1093\/sleepj\/zsx050.675","article-title":"Factors associated with use of different narcolepsy medications and medication discontinuation rates: findings from the Nexus Narcolepsy Registry","volume":"40","author":"Pasta","year":"2017","journal-title":"Sleep"}],"container-title":["Sleep Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945719303090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945719303090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T15:18:47Z","timestamp":1761405527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1389945719303090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":199,"alternative-id":["S1389945719303090"],"URL":"https:\/\/doi.org\/10.1016\/j.sleep.2019.09.001","relation":{},"ISSN":["1389-9457"],"issn-type":[{"value":"1389-9457","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications","name":"articletitle","label":"Article Title"},{"value":"Sleep Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sleep.2019.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}